SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
No proceeds or transaction dates were provided for the Vistagen Therapeutics and Greenland Mines liquidations.
Rhea-AI Summary
SRX Global (SRXH) added an investment in Onconetix (ONCO) and updated shareholders on the liquidation of two portfolio holdings.
The holdings are Vistagen Therapeutics (VTGN) and Greenland Mines (GRML). SRX said it added Onconetix in anticipation of the closing of Onconetix's previously announced agreement to acquire Realbotix. Realbotix developed Vinci, an AI vision system that places cameras and tracking lenses inside robotic eyes. The system is described as detecting motion, recognizing returning users and identifying objects or colors.
Positive
- None.
Negative
- None.
Details
Market Reaction – ONCO
On Sep 24, the day this news came out, the latest delayed price for ONCO is 13.08% above the previous close. Argus tracked a peak move of +18.9% during the session. Our momentum scanner has recorded 42 alerts for this stock so far that day. The latest delayed price is $1.03. Relative volume is exceptionally heavy at 35.4x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Historical Context
-
ONCO arranged up to $5 million in bridge financing for acquisition target Realbotix.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
large language models technical
micro-expressions technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras.
NORTH PALM BEACH, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced an update to shareholders on the liquidation of portfolio holdings Vistagen Therapeutics (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, and Greenland Mines (Nasdaq: GRML), a critical and precious minerals development company.
Additionally, the Company has added an investment in Onconetix Inc. (Nasdaq: ONCO). Onconetix has previously announced an agreement to acquire Realbotix LLC.
Realbotix utilizes a proprietary, patented robotic eyeball technology and an AI vision system known as Vinci. Developed by Realbotix, this hardware and software integration embeds cameras and tracking lenses directly inside the robot's eyeballs, rather than hiding them in the forehead or chest like standard humanoids. The Vinci AI Vision System enables the hardware lenses to detect motion, recognize returning users, and identify objects or colors in the surrounding environment. The in-eye sensors analyze human micro-expressions to gauge emotional states (such as confusion, engagement, or frustration) and automatically adapt the robot's conversation via integrated large language models (LLMs).
About SRX Global Inc.
SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “intend,” “aim,” “plan,” “may,” “could,” “target,” and similar expressions are intended to identify forward-looking statements, including statements regarding the Company’s investment strategy, capital allocation and portfolio positioning, the redeployment of proceeds from the positions described above, the anticipated benefits of the Company’s investment in Onconetix, and the completion, timing and potential benefits of Onconetix’s pending acquisition of Realbotix LLC. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including risks described in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law.
Company Contact
SRX Global Inc.
Kent Cunningham, Chief Executive Officer
Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254
srx@kcsa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What can the Vinci AI Vision system associated with SRX Global's Onconetix investment do?
SRX describes Vinci as using sensors inside robotic eyes to analyze human micro-expressions and adjust a robot's conversation through integrated large language models. The described expressions include confusion, engagement and frustration.